CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,090,000)	$ (2,287,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for services	170,000	480,000
Stock options issued/vested for services	141,000	408,000
Debt discount and original issue discount accretion	424,000
Gain on debt write-off	(33,000)
Amortization of technology license, patents and intellectual property	182,000	121,000
Changes in:
Account receivable	(86,000)	(171,000)
Prepaid expenses and other assets	183,000	166,000
Accounts payable	4,000	67,000
Accrued interest and expenses - related parties	27,000	20,000
Net cash used in operating activities	(1,078,000)	(1,196,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(2,000)
Net cash used in investing activities		(2,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable	400,000	200,000
Payment on related party note payable	(18,000)
Proceeds from issuance of common stock, net of offering costs	630,000	100,000
Net cash provided by financing activities	1,012,000	300,000
NET DECREASE IN CASH AND CASH EQUIVALENTS	(66,000)	(898,000)
Cash and cash equivalents, beginning of period	157,000	1,055,000
CASH AND CASH EQUIVALENTS, END OF PERIOD	91,000	157,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of 14,001,000 common shares for acquisition of Senior Scientific and Scientific Nanomedicine		899,000
Common shares issued for prepaids	105,000
Common shares issued for accrued liabilities	21,000
Recognition of debt discount on warrants associated with debt	120,000	75,000
Unrealized loss on available for sale securities	10,000	33,000
Forgiveness of debt by shareholder and accounted for as additional paid-capital	$ 80,000